AAP
GLUE icon

Arax Advisory Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Arax Advisory Partners’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$773K Buy
31,955
+31,632
+9,793% +$598K 0.01% 1354
2026
Q1 		$8.92K Sell
323
-137
-30% -$2.62K ﹤0.01% 2504
2025
Q4 		$7.21K Sell
460
-31,985
-99% -$431K ﹤0.01% 2655
2025
Q3 		$240K Buy
+32,445
New +$172K ﹤0.01% 1181
2025
Q2 		– Sell
-95
Closed -$441 – 3110
2025
Q1 		$441 Buy
+95
New +$583 ﹤0.01% 2546

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arax Advisory Partners's GLUE Position: Q2 2026 in Review

Arax Advisory Partners increased its Monte Rosa Therapeutics (GLUE) stake by 9,793% in Q2 2026, buying an estimated $598K and bringing the position to 31,955 shares worth $773K. The position accounts for 0.01% of the portfolio, ranked #1354.

Arax Advisory Partners first reported a position in GLUE in Q1 2025 and has held it in 5 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Arax Advisory Partners held 31,955 shares of Monte Rosa Therapeutics worth $773K as of Q2 2026.
  • Arax Advisory Partners bought 31,632 Monte Rosa Therapeutics shares in Q2 2026, an estimated $598K.
  • Monte Rosa Therapeutics made up 0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1354 holding.
  • Arax Advisory Partners first reported a position in Monte Rosa Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.